CUA 2017: Fatigue in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide: Data from Randomized Clinical Trials.
Toronto, Ontario (UroToday.com) Enzalutamide (Enza) is a novel androgen inhibitor with established efficacy in metastatic castration-resistant prostate cancer (CRPC). The AFFIRM and PREVAIL trials established its efficacy in the post-chemotherapy and pre-chemotherapy phases (***). Along with abiraterone (Abi), it is one of two approved oral agents for this disease state. However, the decision to utilize one over the other is often determined by adverse event profiles and contraindications.
CUA 2017: Medication Use and Kidney Cancer Risk: A Population-Based Study
Toronto, Ontario (UroToday.com) Exposure to commonly prescribed medications may be associated with reduced cancer risk; however, there is limited data in kidney cancer. Furthermore, methods of classifying cumulative medication exposure in previous studies may be prone to bias.
CUA 2017: The Role of Delayed Orchiectomy Following Chemotherapy in Metastatic Germ Cell Tumors, The Princess Margaret Cancer Centre Experience
Toronto, Ontario (UroToday.com) Rarely, testicular germ cell tumors (TGCT) present with high-burden metastases and chemotherapy is initiated prior to removal of the clinically diagnosed testicular primary. The standard of care has been orchiectomy post-chemotherapy, as the testicle is considered a sanctuary site at risk for residual disease. However, several small studies have observed complete response in the testicle.
CUA 2017: Phase II Trial of Atezolizumab in Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer
Toronto, Ontario (UroToday.com) Immune checkpoint inhibitors (ICI) are a novel class of agents with promising results in multiple solid organ malignancies, typically in the advanced state. There are now 5 ICI’s approved for metastatic / advanced urothelial cancer (UC). However, while the promise of these therapies has been high, each has been shown to demonstrate an approximately 20% objective response rate (ORR), indicating the importance of patient selection.
CUA 2017: A Cost-Effectiveness Analysis of Hexaminolevulinate Blue Light-Assisted Transurethral Resection of Bladder Tumors in a Universal Healthcare System
Toronto, Ontario (UroToday.com) Bladder surveillance for tumor recurrence and treatment of eventual recurrences account for 60% of the total costs of managing bladder cancer (BCa) patients1 – additional cost effective measures for surveillance and treatment are necessary.
CUA 2017: Impact of Abiraterone Acetate in Post-Docetaxel Setting on the Survival of Metastatic Castration-Resistant Prostate Cancer Patients: A Population-Based Study in Quebec
Toronto, Ontario (UroToday.com) Abiraterone acetate (Abi) is a novel steroidal CYP17A inhibitor that is approved for use for patients with metastatic castration-resistant prostate cancer (CRPC). The COU-AA-301 study1 established its efficacy in a post-docetaxel setting, and ultimately, it was shown to be efficacious in men prior to chemotherapy treatment. Recent results from ASCO 2017 have now demonstrated its efficacy even in hormone-naïve metastatic prostate cancer, when given in conjunction with androgen deprivation therapy (ADT).
CUA 2017: Potential Role of a Novel Urinary Biomarker-Based Risk Score to Select Patients for Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection
Toronto, Ontario (UroToday.com) Introduction of multiparametric MRI (mpMRI) has drastically changed the landscape of prostate cancer (PCa) diagnostics. However, as with any diagnostic tool, learning to better select patients for appropriate use, especially in a cost-effective manner, is critically important. While originally touted to be an excellent discriminator between clinically significant prostate cancer and indolent disease, more recent results have been sobering; false negatives still persist in the range of 10-20%.